Oncolytic Virus Therapies Market Growth Report 2023-2028

1
Global Oncolytic Virus Therapies Market Research
and Forecast Report 2023-2028




Author Elena Anderson, Marketing Manager
IMARC Group
Copyright IMARC Service Pvt Ltd. All Rights
Reserved
2019 IMARC All Rights Reserved
2
About IMARC Group
Report Description
The International Market Analysis Research and
Consulting Group is a leading adviser on
management strategy and market research
worldwide. We partner with clients in all sectors
and regions to identify their highest-value
opportunities, address their most critical
challenges, and transform their
businesses. IMARCs information products include
major market, scientific, economic and
technological developments for business leaders
in pharmaceutical, industrial, and high
technology organizations. Market forecasts and
industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel
and tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Global Oncolytic Virus Therapies Market Research
Report According to the latest report by IMARC
Group, titled Oncolytic Virus Therapies Market
Global Industry Trends, Share, Size, Growth,
Opportunity and Forecast 2023-2028 the global
oncolytic virus therapies market reached a strong
growth in 2022.  Oncolytic virus therapies are a
form of immunotherapy that utilizes viruses to
infect and destroy cancer cells. They use various
natural and genetically modified viruses, such as
herpes simplex, Newcastle disease, vaccinia,
adenovirus, reovirus, and picornavirus. Oncolytic
virus therapies activate danger signals for
generating an immune response and are widely used
for treating solid tumors, melanoma, and
unresectable lesions. They also help eradicate
tumors using viruses that only infect and destroy
targeted tumor cells. As compared to
chemotherapy, oncolytic virus therapies are
non-toxic, provide superior efficacy, and prolong
the survival of cancer patients. As a result,
they find extensive applications in hospitals,
clinics, and cancer research institutes. Request
Free Sample Report https//www.imarcgroup.com/onc
olytic-virus-therapies-market/requestsample
4
Report Description and Highlights
Report Description

Global Oncolytic Virus Therapies Market Trends
The rising incidences of cancer across the
globe are creating a positive outlook for the
market. Oncolytic virus therapies are widely used
to treat various cancers, such as glioblastoma,
breast, lung, and prostate cancers, due to their
powerful anti-tumor properties and ability to
target tumors accurately without harming
surrounding tissues. In line with this, the
widespread utilization of the therapy to treat
various types of melanomas, such as hematological
malignancies, lymphoma, leukemia, and myeloma, is
favoring the market growth. Furthermore, rising
concerns among patients regarding the negative
health impact of various cancer treatments, such
as surgical intervention, radiotherapy,
chemotherapy, and immunotherapy, are providing a
considerable boost to the market growth.
Additionally, the rising number of clinical
studies in oncolytic viruses, such as
herpesvirus, adenovirus, and vaccinia virus, that
is in the final stages and have demonstrated
excellent experimental results are facilitating
the market growth. Other factors, including
rising demand for advanced treatments and novel
therapies and increasing initiatives by several
governments to spread awareness regarding
different causes of cancer and promote early
diagnosis, are anticipated to drive the market
growth. Looking forward, the market value is
projected to reach a strong growth during the
forecast period (2023-2028).
5
Report Description and Highlights
Report Description
Market Summary Breakup by Virus Type
Genetically Engineered Oncolytic Viruses
Herpes Simplex Virus
Adenovirus Vac
cinia Virus Oncolytic Wild-Type Viruses
Reovirus Newca
stle Disease Virus Vesicular Sto
matitis Virus Breakup by Application S
olid Tumors Breast Cancer
Prostate Cancer Lung
Cancer Glioblastoma M
elanoma Hematological Malignanci
es

6
Report Description and Highlights
Report Description
Lymphoma Leuke
mia Myeloma Breakup by End Use
Hospitals Specialty Clinics
Cancer Research Institute
Breakup by Region North America
United States Canada
Asia-Pacific China
Japan India
South Korea Austra
lia Indonesia

7
Report Description and Highlights
Report Description
Others Europe
Germany France
United Kingdom Italy
Spain Russia
Others Latin America
Brazil Mexico
Others Middle East and A
frica Note We are updating our reports, If you
want latest primary and secondary data
(2023-2028) with Cost Module, Business Strategy,
Distribution Channel, etc. Click request free
sample report.

8
Report Description and Highlights
Report Description

• Competitive Landscape with Key Players
• Dnatrix Inc. Genelux Corporation Lokon Pharma AB R
  eplimune Group Inc. Rigvir Ltd. Sorrento Therapeut
  ics Takara Bio Inc. (Takara Holdings Inc.) Targova
  x TILT Biotherapeutics Ltd Transgene SA and Vyriad
  . Kindly note that this only represents a partial
  list of companies and the complete list has been p
  rovided in the report.
• View Full Report with TOC List of Figure
  https//www.imarcgroup.com/oncolytic-virus-therapi
  es-market

9
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
10
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
11
Report Description and Highlights
Report Description

2019 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
12

Contact Us